Harrow, Inc. (HROW): EBITDA
$32.43M
Year ended 2025-12-31
-$880.0K
Trailing 12 months to 2026-06-30
+112.2%
3-year compound annual growth
+70.3%
5-year compound annual growth
| Period ended | EBITDA | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $32.43M | +203.9% | 2026-03-02, From 2025-01-01 |
| 2024-12-31 | $10.67M | +444.2% | 2026-03-02, From 2024-01-01 |
| 2023-12-31 | $1.96M | -42.3% | 2026-03-02, From 2023-01-01 |
| 2022-12-31 | $3.40M | +2.0% | 2024-03-19, From 2022-01-01 |
| 2021-12-31 | $3.33M | +47.1% | 2023-03-23, From 2021-01-01 |
| 2020-12-31 | $2.27M | n/m | 2022-03-10, From 2020-01-01 |
| 2019-12-31 | -$2.86M | n/m | 2021-03-08, From 2019-01-01 |
| 2018-12-31 | -$3.61M | n/m | 2020-03-13, From 2018-01-01 |
| 2017-12-31 | -$10.76M | n/m | 2019-03-12, From 2017-01-01 |
| 2016-12-31 | -$14.83M | n/m | 2018-03-08, From 2016-01-01 |
| 2015-12-31 | -$14.57M | n/m | 2017-03-21, From 2015-01-01 |
| 2014-12-31 | -$10.11M | n/a | 2016-03-23, From 2014-01-01 |
EBITDA at similar companies
| Company | Year ended | EBITDA | Change YoY |
|---|---|---|---|
| Harrow, Inc. (HROW) | 2025-12-31 | $32.43M | +203.9% |
| Vireo Growth Inc. (VREOF) | 2025-12-31 | $15.06M | -6.5% |
| Ligand Pharmaceuticals Inc (LGND) | 2025-12-31 | $74.78M | +491.9% |
| Arvinas, Inc. (ARVN) | 2025-12-31 | -$115.50M | n/m |
| Schrodinger, Inc. (SDGR) | 2025-12-31 | -$160.87M | n/m |
| Xeris Biopharma Holdings, Inc. (XERS) | 2025-12-31 | $26.21M | n/m |
| Ironwood Pharmaceuticals Inc (IRWD) | 2025-12-31 | $99.60M | +5.6% |
| Evolus, Inc. (EOLS) | 2025-12-31 | -$25.16M | n/m |
| Arcus Biosciences, Inc. (RCUS) | 2025-12-31 | -$376.00M | n/m |
Compare HROW, VREOF, LGND, ARVN side by side · Screen every company in Pharmaceutical Preparations ↗